Pharmacokinetics and Pharmacodynamics of AR9281, an Inhibitor of Soluble Epoxide Hydrolase, in Single- and Multiple-Dose Studies in Healthy Human Subjects

Inhibition or Deletion of Soluble Epoxide Hydrolase Prevents Hyperglycemia, Promotes Insulin Secretion, and Reduces Islet Apoptosis

(2010) P. Luo et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Soluble Epoxide Inhibition Is Protective Against Cerebral Ischemia via Vascular and Neural Protection

(2009) Alexis N. Simpkins et al.   AMERICAN JOURNAL OF PATHOLOGY

Soluble Epoxide Hydrolase, a Target with Multiple Opportunities for Cardiovascular Drug Discovery

(2009) Joseph Marino Jr.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Epoxyeicosatrienoic Acid Agonist Rescues the Metabolic Syndrome Phenotype of HO-2-Null Mice

(2009) K. Sodhi et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases

(2009) John D. Imig et al.   NATURE REVIEWS DRUG DISCOVERY

Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo

(2008) Atsuko Motoki et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Soluble Epoxide Hydrolase Inhibitors Reduce the Development of Atherosclerosis in Apolipoprotein E-Knockout Mouse Model

(2008) Arzu Ulu et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Hydrolysis of cis- and trans-Epoxyeicosatrienoic Acids by Rat Red Blood Cells

(2008) H. Jiang et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Soluble Epoxide Hydrolase Gene Deletion Is Protective Against Experimental Cerebral Ischemia

(2008) Wenri Zhang et al.   STROKE